INBX
Inhibrx Biosciences, Inc.
NASDAQ: INBX · HEALTHCARE · BIOTECHNOLOGY
$124.82
-4.47% today
Updated 2026-04-29
Market cap
$1.82B
P/E ratio
—
P/S ratio
1,402.52x
EPS (TTM)
$-9.04
Dividend yield
—
52W range
$11 – $155
Volume
0.3M
Inhibrx Biosciences, Inc. (INBX) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
1 of 8
Last 8 quarters
Avg EPS surprise
-48.2%
Last 4 quarters
Revenue YoY growth
—
Most recent quarter
EPS YoY growth
+31.7%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+5.5%
Last 3 reports
Positive reaction rate
100%
3 of 3 quarters
Largest single-day move
+9.2%
2025-08-13
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-23 | $-2.11 | -29.4% | $60.92 | $63.12 | +3.6% |
| 2025-11-14 | $-2.28 | -45.2% | $74.62 | $77.35 | +3.7% |
| 2025-08-13 | $-1.85 | -19.4% | $21.92 | $23.94 | +9.2% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-1.63 | $-2.11 | -29.4% | — | — |
| 2025-09-30 | $-1.57 | $-2.28 | -45.2% | — | — |
| 2025-06-30 | $-1.55 | $-1.85 | -19.4% | $1.30M | +1200.0% |
| 2025-03-31 | $-1.41 | $-2.80 | -98.6% | — | — |
| 2024-12-31 | $-1.44 | $-3.09 | -114.6% | $100000.00 | — |
| 2024-09-30 | $-1.48 | $-2.84 | -91.9% | — | — |
| 2024-06-30 | $-1.52 | $125.48 | +8355.3% | $100000.00 | — |
| 2024-03-31 | $-1.04 | $-1.44 | -38.5% | — | — |
Frequently asked questions
Has Inhibrx Biosciences, Inc. beaten earnings estimates?
Inhibrx Biosciences, Inc. has beaten Wall Street EPS estimates in 1 of its last 8 quarterly reports, with an average EPS surprise of -48.2% over the last 4 quarters.
How does INBX stock react to earnings?
INBX stock has moved an average of +5.5% in the trading day following earnings over its last 3 reports, with positive reactions in 100% of those quarters.